Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986–2019

BACKGROUND: Insulin is the primary treatment for type 1 and some type 2 diabetes but remains costly in the United States, even though it was discovered more than a century ago. High prices can lead to nonadherence and are often sustained by patents and regulatory exclusivities that limit competition...

Descripción completa

Detalles Bibliográficos
Autores principales: Olsen, Anders, Beall, Reed F., Knox, Ryan P., Tu, Sean S., Kesselheim, Aaron S., Feldman, William B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653475/
https://www.ncbi.nlm.nih.gov/pubmed/37971985
http://dx.doi.org/10.1371/journal.pmed.1004309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653475/
https://www.ncbi.nlm.nih.gov/pubmed/37971985
http://dx.doi.org/10.1371/journal.pmed.1004309

Ejemplares similares